About this Journal Submit a Manuscript Table of Contents
International Journal of Medicinal Chemistry
Volume 2012 (2012), Article ID 159285, 24 pages
http://dx.doi.org/10.1155/2012/159285
Review Article

Current Updates on Oxazolidinone and Its Significance

1Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Jaipur National University, Jagatpura-Jaipur, Rajasthan 302025, India
2Sadbhavna College of Management & Technology, Jalaldiwal, Ludhiana-Barnala State Highway-13, Raikot (Ludhiana), Punjab, India

Received 22 June 2011; Revised 16 October 2011; Accepted 20 October 2011

Academic Editor: Paola Fossa

Copyright © 2012 Neha Pandit et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Vara Prasad, “New oxazolidinones,” Current Opinion in Microbiology, vol. 10, no. 5, pp. 454–460, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. B. Bozdogan and P. C. Appelbaum, “Oxazolidinones: activity, mode of action, and mechanism of resistance,” International Journal of Antimicrobial Agents, vol. 23, no. 2, pp. 113–119, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. K. E. Brighty, W. Kohlbrenner, and P. R. McGuirk, “Chapter 15. Recent developments in antibacterial resistance mechanisms,” Annual Reports in Medicinal Chemistry, vol. 28, pp. 141–150, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Luo, L. Liu, L. Li, and Q. Deng, “Chiral resolution of racemic 4-phenyl(benzyl)-2-oxazolidone by use of molecularly imprinted polymers,” Chromatographia, vol. 65, no. 11-12, pp. 675–679, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. J. Brickner, “Oxazolidinone antibacterial agents,” Current Pharmaceutical Design, vol. 2, no. 2, pp. 175–194, 1996. View at Scopus
  6. N. Alouane, A. Boutier, C. Baron, E. Vrancken, and P. Mangeney, “Remarkably efficient charcoal-promoted ring-closing carbonylations,” Synthesis, no. 5, pp. 860–864, 2006. View at Publisher · View at Google Scholar
  7. A. Buzas and F. Gagosz, “Gold(I)-catalyzed formation of 5-methylene-1,3-oxazolidin-2-ones,” Synlett, no. 17, pp. 2727–2730, 2006. View at Publisher · View at Google Scholar
  8. R. Robles-Machín, J. Adrio, and J. C. Carretero, “Gold-catalyzed synthesis of alkylidene 2-oxazolidinones and 1,3-oxazin-2-ones,” Journal of Organic Chemistry, vol. 71, no. 13, pp. 5023–5026, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. T. Munegumi, I. Azumaya, T. Kato, H. Masu, and S. Saito, “[3+2] Cross-coupling reactions of aziridines with isocyanates catalyzed by nickel(II) iodide,” Organic Letters, vol. 8, no. 3, pp. 379–382, 2006. View at Publisher · View at Google Scholar · View at PubMed
  10. Y. Osa, Y. Hikima, Y. Sato et al., “Convenient synthesis of oxazolidinones by the use of halomethyloxirane, primary amine, and carbonate salt,” Journal of Organic Chemistry, vol. 70, no. 14, pp. 5737–5740, 2005. View at Publisher · View at Google Scholar · View at PubMed
  11. A. Bøgevig, K. Juhl, N. Kumaragurubaran, W. Zhuang, and K. A. Jørgensen, “Direct catalytic asymmetric amination of aldehydes: synthesis of evans oxazolidinones and a-AminoAcid,” Angewandte Chemie International Edition, vol. 41, p. 1790, 2002.
  12. H. P. Buchstaller, “Solid-phase synthesis of oxazolidinones by cycloaddition of resin-bound epoxides with isocyanates,” Journal of Combinatorial Chemistry, vol. 5, no. 6, pp. 789–793, 2003. View at Publisher · View at Google Scholar · View at PubMed
  13. K.-J. Hwang, C.-M. Yu, N.-K. Choi, and K.-H. Park, “A convenient diastereoselective synthesis of oxazolidinone: approach to unusal amino acid statine,” Bulletin of the Korean Chemical Society, vol. 15, pp. 527–532, 1994.
  14. G. Bratulescu, “An excellent procedure for the synthesis of oxazolidin-2-ones,” Synthesis, no. 20, pp. 3111–3112, 2007. View at Publisher · View at Google Scholar
  15. D. M. Gleave, S. J. Brickner, P. R. Manninen et al., “Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones,” Bioorganic and Medicinal Chemistry Letters, vol. 8, no. 10, pp. 1231–1236, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. D. L. Stevens, B. Dotter, and K. Madaras-Kelly, “A review of linezolid: the first oxazolidinone antibiotic,” Expert Review of Anti-Infective Therapy, vol. 2, no. 1, pp. 51–59, 2004. View at Scopus
  17. F. Ntziora and M. E. Falagas, “Linezolid for the treatment of patients with atypical mycobacterial infection: a systematic review,” International Journal of Tuberculosis and Lung Disease, vol. 11, no. 6, pp. 606–611, 2007. View at Scopus
  18. D. Andes, M. L. Van Ogtrop, J. Peng, and W. A. Craig, “In vivo pharmacodynamics of a new oxazolidinone (linezolid),” Antimicrobial Agents and Chemotherapy, vol. 46, no. 11, pp. 3484–3489, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. CIMS, CMP Medica India Private Limited, 2010.
  20. Zurenko, et al., “In vitro antibacterial activity of U-100592 and U-100766, novel oxazolidinones antibiotics,” in Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC '95), pp. 150–11, 1995.
  21. C. W. Ford, et al., in Proceedings of the 35th Internscience Conference on Antimicrobial Agents and Chemotherapy, 1995.
  22. D. J. Abraham, Ed., BURGER’S Medicinal chemistry and drug discovery, vol. 5, Willey Interscience, 6th edition, 1997.
  23. D. J. Abraham, Ed., BURGER’S Medicinal Chemistry and Drug Discovery, vol. 2, Willey Interscience, 1996.
  24. D. J. Diekema and R. N. Jones, “Oxazolidinones: a review,” Drugs, vol. 59, no. 1, pp. 7–16, 2000. View at Scopus
  25. V. A. Pankratov, T. M. Frenkel', and A. M. Fainleib, “2-oxazolidinone,” Russian Chemical Review, vol. 52, no. 6, p. 576, 1983.
  26. B. K. Srivastava, R. Soni, J. Z. Patel, M. R. Jain, and P. R. Patel, “Oxazolidinone antibacterials and our experience,” Anti-Infective Agents in Medicinal Chemistry, vol. 7, no. 4, pp. 258–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. M. R. Barbachyn and C. W. Ford, “Oxazolidinone structure-activity relationships leading to linezolid,” Angewandte Chemie, vol. 42, no. 18, pp. 2010–2023, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. N. Gandhi, B. K. Srivastava, V. B. Lohray, and B. B Lohray, “Novel anti-infective compounds,” Tetrahedron Letters, vol. 45, pp. 6269–6272, 2004.
  29. P. Senci, M. Caspani, F. Ripamonti, and R. Ciabatti, “Oxazolidinone antibacterials and our experience,” Journal of the Chemical Society, Perkin Transactions, vol. 1, p. 2345, 1994.
  30. C. A. Quesnelle, P. Gill, S. Roy et al., “Biaryl isoxazolinone antibacterial agents,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 11, pp. 2728–2733, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. G. Wang, J. R. Ella-Menye, and V. Sharma, “Synthesis and antibacterial activities of chiral 1,3-oxazinan-2-one derivatives,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 8, pp. 2177–2181, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. R. Griera, C. Cantos-Llopart, M. Amat, J. Bosch, J.–C. del Castillo, and J.B Huguet, “New potential antibacterials: a synthetic route to N-aryloxazolidinone/3-aryl tetrahydroisoquinoline hybrids,” Bioorganic & Medicinal Chemistry Letters, vol. 15, p. 2515, 2005.
  33. M. L. Hammond and Y. Fukuda, “Oxazolidinones antibiotics and derivatives,” Pct International Application WO2005/005399, Merck & Co.-Kyorin Pharmaceutical, 2005.
  34. N. Selvakumar, B. Yadi Reddy, G. Sunil Kumar et al., “Synthesis of novel tricyclic oxazolidinones by a tandem SN2 and SNAr reaction: SAR studies on conformationally constrained analogues of Linezolid,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 16, pp. 4416–4419, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. A. L. Choy, J. V. N. Vara Prasad, F. E. Boyer, M. D. Huband, and M. R. Dermyer, “Synthesis and SAR of novel conformationally restricted oxazolidinones possessing Gram-positive and fastidious Gram-negative antibacterial activity. Part 2: Amino substitutions on heterocyclic D-ring system,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 16, pp. 4699–4702, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. B. B. Lohray, V. B. Lohray, B. K. Srivastava et al., “Oxazolidinone: search for highly potent antibacterial,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 12, pp. 3139–3142, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. B. K. Srivastava, P. B. Kapadnis, P. Pandya, and V. B. Lohray, “Novel Mannich ketones of oxazolidinones as antibacterial agents,” European Journal of Medicinal Chemistry, vol. 39, no. 11, pp. 989–992, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. B. Das, S. Rudra, A. Yadav, et al., “Synthesis and antibacterial activity of potent heterocyclic oxazolidinones and the identification of RBx 8700,” Bioorganic and Medicinal Chemistry Letters, vol. 15, p. 4261, 2005.
  39. S. K. Agrawal, S. S. Pandey, M. M. Samuel, G. Singh, and S. Chithra, “New antibacterial agents,” Pct International Application number WO2005/090339, Orchid Chemicals and Pharmaceuticals, 2005.
  40. A. R. Renslo, G. W. Luehr, S. Lam et al., “Synthesis and structure-activity studies of antibacterial oxazolidinones containing dihydrothiopyran or dihydrothiazine C-rings,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 13, pp. 3475–3478, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. X. Zhai, G. G. Zhang, D. H. Gou, J. P. Liu, and P. Gong, “Modification of novel oxazolidinone derivatives at C-5 side chain and their antibacterial activities,” Acta Pharmaceutica Sinica, vol. 41, no. 10, pp. 985–989, 2006. View at Scopus
  42. R. Schaadt, D. Sweeney, D. Shinabarger, and G. Zurenko, “The in vitro activity of TR-701, a novel oxazolidinone antibacterial agent,” in Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC '07), Chicago, Ill, USA, September 2007.
  43. B. Das, S. Rudra, S. Sangita, M. Salman, and A. Rattan, “Oxazolidinone derivatives as antimicrobials,” Pct International Application number WO2006/109156, Ranbaxy Laboratories, 2006.
  44. O. A. Phillips, E. E. Udo, A. A. M. Ali, and S. M. Samuel, “Structure-antibacterial activity of arylcarbonyl- and arylsulfonyl-piperazine 5-triazolylmethyl oxazolidinones,” European Journal of Medicinal Chemistry, vol. 42, no. 2, pp. 214–225, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. H. Fan, Y. Chen, Z. Jiang et al., “Synthesis and biological evaluation of new N-linked 5-triazolylmethyl oxazolidinones,” European Journal of Medicinal Chemistry, vol. 43, no. 8, pp. 1706–1714, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. N. Selvakumar, G. S. Kumar, A. Malar Azhagan et al., “Synthesis, SAR and antibacterial studies on novel chalcone oxazolidinone hybrids,” European Journal of Medicinal Chemistry, vol. 42, no. 4, pp. 538–543, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. F. Reck, F. Zhou, C. J. Eyermann et al., “Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility,” Journal of Medicinal Chemistry, vol. 50, no. 20, pp. 4868–4881, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. J. Liu, B. He, A. Yu, and W. Zhou, “Synthesis and antibacterial activity of substituted oxotriazolylphenyl oxazolidinones,” Chemical Biology and Drug Design, vol. 70, no. 1, pp. 65–69, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. T. J. Poel, R. C. Thomas, W. J. Adams et al., “Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-fluoro-4-(1-oxotetrahydrothiopyran-4-yl)phenyl] -2-oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound,” Journal of Medicinal Chemistry, vol. 50, no. 24, pp. 5886–5889, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. S. Rudra, A. Yadav, A. V. S. Raja Rao et al., “Synthesis and antibacterial activity of potent heterocyclic oxazolidinones and the identification of RBx 8700,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 24, pp. 6714–6719, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. F. Reck, F. Zhou, G. Zainoun, D. Carcanague, C. Eyermann, and M. Gravestock, “Novel acyclic substituted (pyridin-3-yl) phenyl oxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and improved solubility,” in Proceedings of the 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March-April 2007.
  52. M. Cano, A. Palomer, and A. Guglietta, “Oxazolidinone derivatives and use thereof as antibiotics,” Pct International Application number WO2007/000432, Ferrer International S.A., 2007.
  53. B. K. Srivastava, R. Soni, J. Z. Patel, M. R. Jain, and P. R. Patel, “Oxazolidinone antibacterials and our experience,” Anti-Infective Agents in Medicinal Chemistry, vol. 7, no. 4, pp. 258–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. J. F. Barrett, “Linezolid pharmacia corp,” Current Opinion in Investigational Drugs, vol. 1, no. 2, pp. 181–187, 2000. View at Scopus
  55. Y. Cui, Y. Dang, Y. Yang, S. Zhang, and R. Ji, “Antibacterial activity of YC-20, a new oxazolidinone,” Journal of Antimicrobial Chemotherapy, vol. 58, no. 2, pp. 452–454, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. S. Lemaire, K. Kosowska-Shick, P. C. Appelbaum, P. M. Tulkens, and F. Van Bambeke, “Radezolid (RX RX-1741), a novel oxazolidinone oxazolidinone, accumulates, extensively within human macrophages and PMNs and shows activity towards intracellular linezolid linezolid-sensitive and linezolid linezolid-resistant Staphylococcus aureus,” in Proceedings of the 26th International Congress of Chemotherapy and Infection, Torranto, Canada, June 2009.
  57. http://www.rib-x.com/pipeline/rx_1741.
  58. S. D. Brown and M. M. Traczewski, “Comparative in Vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 5, pp. 2063–2069, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. A. Wookey, P. J. Turner, J. M. Greenhalgh, M. Eastwood, J. Clarke, and C. Sefton, “AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro,” Clinical Microbiology and Infection, vol. 10, no. 3, pp. 247–254, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. A. P. Johnson, M. Warner, and D. M. Livermore, “In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci,” Journal of Antimicrobial Chemotherapy, vol. 50, no. 1, pp. 89–93, 2002. View at Scopus
  61. B. K. Srivastava, P. B. Kapadnis, P. Pandya, and V. B. Lohray, “Novel Mannich ketones of oxazolidinones as antibacterial agents,” European Journal of Medicinal Chemistry, vol. 39, no. 11, pp. 989–992, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. J. A. Demaray, J. E. Thuener, M. N. Dawson, and S. J. Sucheck, “Synthesis of triazole-oxazolidinones via a one-pot reaction and evaluation of their antimicrobial activity,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 17, pp. 4868–4871, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. N. Adibpour, A. Khalaj, and S. Rajabalian, “Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,” European Journal of Medicinal Chemistry, vol. 45, no. 1, pp. 19–24, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. O. A. Phillips, E. E. Udo, M. E. Abdel-Hamid, and R. Varghese, “Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones,” European Journal of Medicinal Chemistry, vol. 44, no. 8, pp. 3217–3227, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. O. A. Phillips, E. E. Udo, A. A. M. Ali, and N. Al-Hassawi, “Synthesis and antibacterial activity of 5-substituted oxazolidinones,” Bioorganic and Medicinal Chemistry, vol. 11, no. 1, pp. 35–41, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Fan, G. Xu, Y. Chen et al., “Synthesis and antibacterial activity of oxazolidinones containing triazolyl group,” European Journal of Medicinal Chemistry, vol. 42, no. 8, pp. 1137–1143, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. Oral anticoagulant rivaroxaban (Xarelto) cuts deep vein thrombosis risk by 82%: Bayer, http://www.dancewithshadows.com/pillscribe/oral-anticoagulant-rivaroxaban-xarelto-cuts-deep-vein-thrombosis-risk-by-82-bayer/.
  68. S. Roehrig, A. Straub, J. Pohlmann et al., “Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4- (3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor,” Journal of Medicinal Chemistry, vol. 48, no. 19, pp. 5900–5908, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. M. R. Barbachyn, D. K. Hutchinson, S. J. Brickner et al., “Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 680–685, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. M. H. Cynamon, S. P. Klemens, C. A. Sharpe, and S. Chase, “Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 5, pp. 1189–1191, 1999. View at Scopus
  71. R. R. Ramsay and M. B. Gravestock, “Monoamine oxidases: to inhibit or not to inhibit,” Mini Reviews in Medicinal Chemistry, vol. 3, no. 2, pp. 129–136, 2003. View at Scopus
  72. A. Malnoe and M. Strolin Benedetti, “Metabolic fate of 3-(3-methylphenyl)-5-hydroxymethyl-2-oxazolidone (toloxatone), a new antidepressant agent, in man,” Xenobiotica, vol. 9, no. 5, pp. 281–288, 1979. View at Scopus
  73. W. Kostowski, A. Plaznik, A. Bidzinski, E. Rosnowska, M. Jessa, and M. Nazar, “Studies on antidepressant action of a new oxazolidinone derivative AS-8,” Polish Journal of Pharmacology, vol. 46, no. 1-2, pp. 15–20, 1994. View at Scopus
  74. S. Katsumura, S. Iwama, T. Matsuda, T. Tani, S. Fujii, and K. Ikeda, “Synthesis of oxazolidinone phospholipid analogue as a new inhibitor of phospholipase A2,” Bioorganic and Medicinal Chemistry Letters, vol. 3, no. 12, pp. 2703–2706, 1993. View at Publisher · View at Google Scholar
  75. J. A. Sternberg, D. Geffken, and J. B. Adams Jr., “Oxazolidinones: a new class of agricultural fungicides,” in Synthesis and Chemistry of Agrochemicals, vol. 686 of ACS Symposium Series, chapter 22, pp. 216–227, 1998.
  76. J. A. Sternberg, D. Geffken, J. B. Adams et al., “Famoxadone: the discovery and optimisation of a new agricultural fungicide,” Pest Management Science, vol. 57, no. 2, pp. 143–152, 2001. View at Scopus
  77. D. B. Jordan, R. S. Livingston, and J. J. Bisaha, “Oxazolidinones: a new chemical class of fungicides and inhibitors of mitochondrial cytochrome bc1 function,” Pesticide Science, vol. 55, no. 2, pp. 213–215, 1999.
  78. W. J. Welstead, G. C. Helsley, C. R. Taylor et al., “5-(2-Aminoethyl)-2-oxazolidinones with central nervous system depressant and antiinflammatory activity,” Journal of Medicinal Chemistry, vol. 16, no. 10, pp. 1129–1132, 1973. View at Scopus
  79. “Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of CNS disorders,” United States Patent, 5643907.
  80. M. Masaki and H. Shinozaki, “A new class of potent centrally acting muscle relaxants: pharmacology of oxazolidinones in rat decerebrate rigidity,” British Journal of Pharmacology, vol. 89, no. 1, pp. 219–228, 1986. View at Scopus
  81. H. J. Lewerenz, D. W. Bleyl, and W. Schnaak, “Effects of 5-vinyloxazolidine-2-thione on lactating rats and their sucklings,” Die Nahrung, vol. 36, no. 4, pp. 388–393, 1992. View at Scopus
  82. N. Zenker, L. S. Hubbard, and J. Wright, “Inhibition of dopamine β-hydroxylase by goitrin, a natural antithyroid compound,” Journal of Natural Products, vol. 51, no. 5, pp. 862–865, 1988. View at Scopus
  83. M. McMillan, E. A. Spinks, and G. R. Fenwick, “Preliminary observations on the effect of dietary Brussels sprouts on thyroid function,” Human Toxicology, vol. 5, no. 1, pp. 15–19, 1986. View at Scopus
  84. M. Artico, G. De Martino, and R. Giuliano, “Research on compounds with antiblastic activity. XL. Synthesis of 3-p-(2',5'-dimethoxy-4'-(N,N-bis-( -chloroethyl)-amino)benzylideneamino)phenyl-2-oxazolidinone (GEA 29 ; BAY a 5850) and its analogues,” Il Farmaco; Edizione Scientifica, vol. 26, no. 9, pp. 771–783, 1971. View at Scopus
  85. H. Onda, F. M. E. Wagenlehner, N. Lehn, and K. G. Naber, “In vitro activity of linezolid against Gram-positive uropathogens of hospitalized patients with complicated urinary tract infections,” International Journal of Antimicrobial Agents, vol. 18, no. 3, pp. 263–266, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. http://www.chemicalbook.com/ChemicalProductProperty_EN_CB71179461.htm.
  87. D. G. Musson, S. M. Maglietto, and S. S. Hwang, “Simultaneous quantification of cycloserine and its prodrug acetylacetonylcycloserine in plasma and urine by high-performance liquid chromatography using ultraviolet absorbance and fluorescence after post-column derivatization,” Journal of Chromatography, vol. 414, no. 1, pp. 121–129, 1987.
  88. T. Mathur, M. Kumar, T. K. Barman et al., “Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 5, pp. 1087–1095, 2011. View at Publisher · View at Google Scholar · View at PubMed
  89. E. Skripkin, T. S. McConnell, J. DeVito et al., “Rχ-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 10, pp. 3550–3557, 2008. View at Publisher · View at Google Scholar · View at PubMed
  90. J. J. Hilliard, J. Fernandez, J. Melton et al., “In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 5, pp. 2028–2033, 2009. View at Publisher · View at Google Scholar · View at PubMed
  91. J. B. Locke, M. Hilgers, and K. J. Shaw, “Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700),” Antimicrobial Agents and Chemotherapy, vol. 53, no. 12, pp. 5265–5274, 2009. View at Publisher · View at Google Scholar · View at PubMed
  92. J. B. Locke, G. Morales, M. Hilgers et al., “Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 12, pp. 5352–5355, 2010. View at Publisher · View at Google Scholar · View at PubMed
  93. E. Y. Cheung, M. L. Peterson, R. Chiarella, and B. M. Foxman, “A novel oxazolidinone anti-biotic: RWJ-416457,” Acta Crystallographica Section C, vol. 66, no. 5, pp. o249–o251, 2010. View at Publisher · View at Google Scholar · View at PubMed
  94. J. B. Locke, J. Finn, M. Hilgers et al., “Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 12, pp. 5337–5343, 2010. View at Publisher · View at Google Scholar · View at PubMed
  95. New Phase 4 Study Shows Higher Rates of Clinical and Microbiological Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia, http://www.prnewswire.com/news-releases/new-phase-4-study-shows-higher-rates-of-clinical-and-microbiological-success-for-zyvox-versus-vancomycin-in-mrsa-nosocomial-pneumonia-105422943.html.